Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

Rhea-AI Summary

Oncolytics Biotech® Inc. President and CEO, Dr. Matt Coffey, will join the Viral Approaches in Oncology panel at Canaccord Genuity's Horizons in Oncology Virtual Conference on April 15, 2024. The company will also hold virtual investor meetings at the conference.

SAN DIEGO and CALGARY, AB, April 2, 2024 /PRNewswire/ -- Oncolytics Biotech^® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that President and Chief Executive Officer Dr. Matt Coffey will participate in the Viral Approaches in Oncology panel at Canaccord Genuity's Horizons in Oncology Virtual Conference, which is taking place on April 15, 2024. Additional details on the panel presentation can be found below.

Date: Monday, April 15, 2024
Time: 9:00 a.m. ET
Panel Title: Viral Approaches in Oncology

A live webcast of the panel presentation will be available to registered attendees of the conference through the conference website. Company management will also be participating in virtual one-on-one investor meetings at the conference. To schedule a meeting, contact your Canaccord representative or email jpatton@oncolytics.ca.

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in Phase 2 studies in breast and pancreatic cancers. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.

Company Contact 
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca

Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com 

Logo - https://mma.prnewswire.com/media/2376873/Oncolytics_Biotech_New_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-participate-in-a-panel-presentation-at-canaccord-genuitys-horizons-in-oncology-virtual-conference-302105507.html

SOURCE Oncolytics Biotech® Inc.

FAQ

When will Dr. Matt Coffey participate in the Viral Approaches in Oncology panel?

Dr. Matt Coffey will participate in the Viral Approaches in Oncology panel on April 15, 2024.

What is the title of the panel Dr. Matt Coffey will join?

Dr. Matt Coffey will join the Viral Approaches in Oncology panel.

Where can registered attendees watch the live webcast of the panel presentation?

Registered attendees can watch the live webcast of the panel presentation through the conference website.

How can one schedule a virtual one-on-one investor meeting with company management?

To schedule a virtual one-on-one investor meeting, contact your Canaccord representative or email jpatton@oncolytics.ca.